For most patients with significant obesity, the risk-benefit calculation currently favors retatrutide but the full picture will take years of post-market data to complete
The MindBody GLP-1 System A Closer Look The MindBody GLP-1 System is a unique approach that connects both physical and mental health for total well-being
Subsequently, Novo Nordisk developed an oral formulation Rybelsus, the first launched oral GLP-1RA, by combining semaglutide with intestinal permeation enhancer SNAC [7][8]
Based on these findings, a new prognostic index was developed, namely, the FA-IPSS-R
Harring M, Golabi P, Paik JM, Shah D, Racila A, Cable R, et al
Sodiumglucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both improve cardiovascular outcomes, but their comparative roles in HF and the potential value of combination therapy remain uncertain